65 patents
Page 2 of 4
Utility
Measuring Container, Loading Tool, and Measuring Container Kit
21 Jul 22
A measuring container comprises a storage container and a storage section selector.
Masaki HAYAKAWA
Filed: 8 Apr 20
Utility
Controlled-release preparation
12 Jul 22
An object of the present invention is to provide a controlled-release preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide as an active ingredient and having an excellent release property.
Shouji Furuta, Naoto Hattori
Filed: 15 Nov 18
Utility
Crystal of compound having JAK-inhibiting activity
5 Jul 22
Fumi Higuchi
Filed: 29 Sep 20
Utility
Antisense Nucleic Acids
26 May 22
Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene.
Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 30 Jun 21
Utility
Method for Inducing Muscular Cells Using Cells In Spot Urine
12 May 22
A method for preparing myotubes in a non-invasive and simple manner and establishes an in vitro test system of an agent used for exon skipping therapy for muscular dystrophy.
Hotake TAKIZAWA, Yoshitsugu AOKI, Shin'ichi TAKEDA, Yukiko ENYA, Yuichiro TONE
Filed: 25 Dec 18
Utility
Myostatin Signal Inhibitor
21 Apr 22
The present invention provides a new approach for inhibiting myostatin signaling by targeting ACVR2B at the mRNA level.
Shinichiro NAKAGAWA
Filed: 26 Dec 19
Utility
Antisense Nucleic Acids
17 Feb 22
Provided is a drug that allows highly-efficient skipping of exon.
Naoki WATANABE, Yuuichirou TONE, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 2 Nov 21
Utility
1,3,4-OXADIAZOLONE Compound and Pharmaceutical
27 Jan 22
Hirotaka KAMITANI, Hisaaki ZAIMOKU, Yoshinari HARUTA, Takeo KIKUCHI
Filed: 14 Nov 19
Utility
Antisense nucleic acids
7 Dec 21
Provided is a drug that allows highly-efficient skipping of exon.
Naoki Watanabe, Yuuichirou Tone, Shin'ichi Takeda, Tetsuya Nagata
Filed: 15 Aug 17
Utility
Azabenzimidazole Compounds and Pharmaceutical
2 Dec 21
The purpose of the present invention is to provide compounds having an M3 PAM action.
Kouya OIKAWA, Sho HIRAI, Kazuhiko WAKITA, Akiko FUJIBAYASHI
Filed: 7 May 19
Utility
Antisense Nucleic Acids
4 Nov 21
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 14 Jul 21
Utility
Antisense Nucleic Acids
16 Sep 21
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 28 May 21
Utility
Method for Preparing Oligonucleic Acid Compound
26 Aug 21
Yutaro KOTOBUKI, Fumiya URABE
Filed: 10 May 19
Utility
Composition Comprising Antisense Oligonucleotide and Use Thereof for Treatment of Duchenne Muscular Dystrophy
26 Aug 21
The present invention relates to a composition containing an antisense oligonucleotide, and the use thereof to treat Duchenne muscular dystrophy.
Tomonori UNO, Takashi NATSUKAWA, Youichi EGAWA, Youhei SATOU
Filed: 26 Jun 19
Utility
Antisense Nucleic Acids
22 Jul 21
Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 21 Aug 20
Utility
Antisense nucleic acids
6 Jul 21
Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene.
Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
Filed: 11 Jun 19
Utility
Antisense Nucleic Acids
1 Jul 21
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 12 Feb 21
Utility
Antisense Nucleic Acids
17 Jun 21
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 18 Dec 20
Utility
Antisense nucleic acids
8 Jun 21
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
Filed: 12 Feb 21
Utility
Antisense Nucleic Acids
20 May 21
The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
Filed: 17 Nov 20